Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Non-Current Deffered Revenue (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Non-Current Deffered Revenue for 14 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $5.9 million; the TTM value through Dec 2025 reached $5.9 million, changed 0.0%, while the annual FY2025 figure was $5.9 million, 0.0% changed from the prior year.
  • Non-Current Deffered Revenue hit $5.9 million in Q4 2025 for Sangamo Therapeutics, roughly flat from $5.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $222.3 million in Q1 2021 and bottomed at $1.8 million in Q1 2023.
  • Average Non-Current Deffered Revenue over 5 years is $93.6 million, with a median of $112.5 million recorded in 2022.
  • Year-over-year, Non-Current Deffered Revenue soared 195.29% in 2021 and then crashed 98.79% in 2023.
  • Sangamo Therapeutics' Non-Current Deffered Revenue stood at $166.8 million in 2021, then plummeted by 34.42% to $109.4 million in 2022, then crashed by 98.34% to $1.8 million in 2023, then soared by 223.46% to $5.9 million in 2024, then changed by 0.0% to $5.9 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $5.9 million, $5.9 million, and $5.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.